MVIR — Medivir AB Share News
0.000.00%
Last trade - 00:00- SEK926.91m
- SEK673.41m
- SEK8.51m
Brief: Medivir Receives Notice Of Allowance For Fostrox Plus Lenvatinib Combination Patent In Japan
Brief: Medivir Q1 Adjusted EBITDA SEK -12.6 Million
Brief: Medivir Gets European Patent For Fostrox Plus Lenvatinib
Brief: Medivir's Partner Infex Therapeutics Signs License Agreement In India
Brief: Medivir Does Not Propose Dividend For FY 2024
Brief: Medivir Q4 Adjusted Free Cash Flow SEK -29.4 Million
Brief: Medivir Obtains Ind Approval For Fostrox
Brief: Medivir Q3 Adjusted EBITDA SEK -35.1 Million
Brief: Medivir To Collaborate With Eisai
Brief: Medivir Gets Loan Facility Of SEK 30 Million
Brief: Medivir Q2 Revenue SEK 1.1 Million
Brief: Medivir Selects Global CRO Partner For Phase 2B Study
Brief: Medivir's Licensee Tango Therapeutics Discontinues Development Of Its TNG348 Clinical Program
Brief: Medivir Q1 Adjusted Free Cash Flow SEK -35 Million
Brief: FDA Grants Medivir's MIV-711 Rare Pediatric Disease Designation
Brief: Medivir Q4 Revenue SEK 4.4 Million
Brief: Medivir Says Carries Out Directed Share Issue Of Approx. SEK 20 Mln
Brief: Medivir Says Co Carries Out A Directed Share Issue Of Approx. Sek 20 Mln
Brief: Medivir Raises About SEK 129 Million In Rights Issue